Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - NSCLC metastatic 2

LBA53 - Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study

Date

21 Sep 2020

Session

Proffered Paper - NSCLC metastatic 2

Topics

Immunotherapy;  Non-Small Cell Lung Cancer

Presenters

Fabrice Barlesi

Citation

Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325

Authors

F. Barlesi1, L. Greillier2, F. Monville3, C. Foa4, J. le treut5, C. Audigier-Valette6, F. Vély7, S. Garcia8, F. Sabatier9, J. Ciccolini10, M. Fabre7, M. Le Ray11, N. Resseguier12, P. Outters13, M. Roumieux14, J. Mazieres15, M. Pérol16, E. Vivier17, P. Auquier18, J. Fieschi13

Author affiliations

  • 1 Gustave Roussy Cancer Campus &, Aix-Marseille University, CRCM, APHM, Marseille, 94805 - Villejuif/FR
  • 2 Multidisciplinary Oncology And Therapeutic Innovations, Hopital Nord, 13015 - Marseille/FR
  • 3 Luminy Biotech Entreprises, HalioDx, 13288 - Marseille Cedex/FR
  • 4 Oncology, Hôpital St Joseph, Marseille/FR
  • 5 Pneumologie, hopital européen Marseille, 13003 - marseille/FR
  • 6 Pneumology, Hospital Sainte Musse, 83100 - Toulon/FR
  • 7 Marseille-immunopole, APHM, 13385 - Marseille cedex /FR
  • 8 Pathology Hopital Nord, Aix Marseille Université CRCM -APHM, Marseille/FR
  • 9 Vascular Biology Department, APHM Hôpital Conception, Marseille/FR
  • 10 Crcm Smartc Platform, Aix-Marseille University - Faculté de Pharmacie, Marseille/FR
  • 11 Cepcm- Clip2, APHM Hôpital de La Timone, Marseille/FR
  • 12 Service D’epidémiologie Et D’economie De La Santé, APHM, 13005 - Marseille/FR
  • 13 Luminy Biotech Entreprises, HalioDx, 13288 - Marseille Cedex /FR
  • 14 Cepcm- Clip2 Timone, Aix Marseille Université - CRCM, Marseille/FR
  • 15 Thoracic Oncology Department, CHU Toulouse - Hôpital Larrey, 31059 - Toulouse/FR
  • 16 Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 17 Service D’immunologie, Hôpital De La Timone ; Innate Pharma Research Labs, Aix-Marseille Université CNRS INSERM APHM Innate Pharma, Marseille/FR
  • 18 Service D’epidémiologie Et D’economie De La Santé, APHM, Marseille/FR
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA53

Background

PIONeeR aims to predict response/resistance to PD1/L1 ICIs in advanced NSCLC pts through comprehensive agnostic multiparametric and longitudinal biomarkers assessment. These ICIs significantly improve long-term outcome in 20% of advanced NSCLC pts but to date, no robust biomarker predicts primary or secondary resistance.

Methods

Advanced NSCLC pts with available archived tumor tissue treated with either nivolumab, pembrolizumab or atezolizumab, alone (2nd line min) or combined with chemotherapy (1st line), were systematically re-biopsied and blood-sampled at 6wks (V2) of treatment. ORR was assessed by RECIST 1.1 every 6wks. Quantification of circulating and tumor infiltrating immune cells and PD-L1 mediated inhibition (Immunoscore® IC) were performed by FACS and multiplex IHC coupled to digital pathology respectively. Endothelial activation, blood soluble factors, PK and TMB through WES were also assessed.

Results

The first 100 pts are mainly male (64%), smokers (91-8%), <65yrs (55%), with an ECOG PS0/1 (97%), treated in 2nd line setting (86%). Tumors were mainly ADC (57%) with ≥1% PDL1 expression in 38% of the cases. 21% were still on treatment at data cut-off. V2 biopsy was available in 46% of cases; 33 pts progressed before the 6wks milestone, and 13 pts were considered as responders. Median PFS was 2.99 months (mo) [95%CI: 2.43 – 4.83] and median OS was 11.01 mo [95%CI: 8.21 - NA]. At baseline (VS), PD-L1 tumor cell percentage was significantly higher in responders, as well as tumor infiltration by cytotoxic lymphocytes (cTILs) (median: 160 vs 410 cells/mm2). Five non-responders presented high cTILs densities (up to 1800 cells/mm2), associated either to no PDL1 expression, high infiltration of Treg cells in the tumor or weak PD1 expression on cTILs. High immune cell densities at the periphery and in the tumor were associated with survival. Immune cell infiltration and PD-L1+ cell density increased from VS to V2, as well as proximity between these cells. Massive PK variability among patients was found.

Conclusions

Immune cells quantification and characterization add value to clinical factors to predict advanced NSCLC response/resistance to ICIs.

Clinical trial identification

NCT03493581, Release date: February 2018.

Editorial acknowledgement

Legal entity responsible for the study

Assistance Publique Hôpitaux de Marseille (AP-HM).

Funding

French National Research Agency (ANR-17-RHUS-0007).

Disclosure

F. Barlesi: Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): ACEA; Research grant/Funding (institution): Amgen; Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): Bayer; Honoraria (self), Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant/Funding (institution): Boehringer-Ingelheim; Research grant/Funding (institution): Eisai; Honoraria (self), Research grant/Funding (institution): Eli Lilly Oncology; Honoraria (self), Research grant/Funding (institution): F. Hoffmann-La Roche Ltd.; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Ipsen; Research grant/Funding (institution): Ignyta; Research grant/Funding (institution): Innate Pharma; Research grant/Funding (institution): Loxo; Research grant/Funding (institution): MedImmune; Honoraria (self), Research grant/Funding (institution): Novartis; Honoraria (self), Research grant/Funding (institution): Merck; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self), Research grant/Funding (institution): Pierre Fabre; Honoraria (self), Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Sanofi-Aventis; Honoraria (self), Research grant/Funding (institution): Takeda. F. Monville: Full/Part-time employment: HalioDx. J. le treut: Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Boehringer; Honoraria (self): Roche. C. Audigier-Valette: Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer Ingelheim; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Travel/Accommodation/Expenses: Lilly; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (institution), Advisory/Consultancy: MSD; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy: AbbVie; Advisory/Consultancy: FoundationOne; Advisory/Consultancy: Takeda. S. Garcia: Travel/Accommodation/Expenses: MSD. J. Ciccolini: Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Research grant/Funding (institution): Institut Roche; Honoraria (self): Pierre Fabre; Honoraria (self): BMS; Honoraria (self): Novartis; Honoraria (self): Lilly; Honoraria (self): Ipsen. P. Outters: Full/Part-time employment: HalioDx. J. Mazieres: Honoraria (self), Research grant/Funding (self): Roche; Honoraria (self), Research grant/Funding (self): AstraZeneca; Honoraria (self), Research grant/Funding (self): Pierre Fabre; Honoraria (self): Takeda; Honoraria (self), Research grant/Funding (self): BMS; Honoraria (self): MSD; Honoraria (self): Hengrui; Honoraria (self): Blueprint; Honoraria (self): Daiichi; Honoraria (self): Novartis. M. Pérol: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Eli Lilly; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Speaker Bureau/Expert testimony: Amgen; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: Takeda; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Chugai. E. Vivier: Shareholder/Stockholder/Stock options, Full/Part-time employment, Officer/Board of Directors: Innate Pharma. J. Fieschi: Officer/Board of Directors: HalioDx. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.